Drug Trial Radar · NCT07510802
Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC
Last checked: Nov 20, 2026Latest source record: Apr 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Feb 2, 2026
Primary completion
Mar 14, 2027
Study completion Apr 17, 2028
Sponsor
- Lead sponsor
- Beijing BiotechIndustry
- Sponsor type
- Industry
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study tests the safety and preliminary anti-tumor activity of an investigational dual-target chimeric antigen receptor natural killer (CAR-NK) cell therapy in adults with advanced breast cancer. After a tumor antigen assessment (HER2/ERBB2, MUC1, ROR1,TNBC cases mesothelin), each participant will receive the most suitable dual-target CAR-NK product for their tumor profile, following short-course lymphodepleting chemotherapy.
Conditions
- Breast Cancer (Advanced/Metastatic)
- HER2-positive Breast Cancer
- Triple-negative Breast Cancer
Interventions
Dual-target CAR-NK cellsBiological
Route: IV infusion. Schedule: single infusion on Day 0; optional second infusion on Day 7 in the absence of dose-limiting toxicity (DLT) and with adequate clinical status.
LymphodepletingDrug
chemotherapy - fludarabine (Days -5 to -3) and cyclophosphamide (Days -5 to -4), prior to CAR-NK infusion.
Supportive careOther
Premedication per institutional standard (e.g., acetaminophen and antihistamine). Tumor lysis and infection prophylaxis per institutional guidelines.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs)Time frame: 28 days
- Recommended Phase 2 Dose (RP2D) based on overall safetyTime frame: 56 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.